CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Lisapharma is developing Edroma, a nanotechnology-based treatment for high-grade gliomas, a type of aggressive brain cancer. This innovative product encapsulates the active ingredient zoledronic acid in nanoparticles, aiming to improve treatment efficacy and reduce toxicity compared to existing therapies.
Lisapharma, an Italian pharmaceutical SME, aims to bring on the market Edroma: a new product based on a nanotechnology platform to treat malignant high-grade gliomas (HGG), for which there are no satisfactory curative methods.
High-grade gliomas are the most aggressive type of brain cancer.
Despite recent advances in treatment, the prognosis for patients with HGG is dismal: so far the most effective treatment, radiotherapy, brings an increase in median survival from 3-4 months to around 9-10.
Th…
LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA SPA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
